09/10/2024
We are thrilled to announce that iProtics has secured its first investment, receiving €350,000 from UNIIQ the Zuid-Holland innovation fund. This significant investment is part of UNIIQ's broader commitment of €2.5 million to seven startups pushing the boundaries of innovation in fields like deep tech, software, and life sciences.
iProtics, a spin-off from Leiden University’s Overkleeft group, is dedicated to developing next-generation immunoproteasome inhibitors with unprecedented selectivity. These inhibitors target diseased cells, such as blood cancer cells, without affecting healthy tissues, potentially revolutionizing treatment for cancers, autoimmune disorders, and other diseases driven by immunoproteasome dysfunction.
The backing from UNIIQ will accelerate our research and development efforts, helping us move closer to offering a novel therapeutic solution that addresses significant unmet medical needs. By honing in on immunoproteasomes, we aim to minimize the side effects commonly associated with existing treatments and provide more effective, targeted therapies for patients.
We are honored to be part of this diverse group of startups recognized by UNIIQ, and we look forward to leveraging this partnership to further our innovations in the life sciences sector. This investment not only reinforces the strength of South Holland's innovation ecosystem but also opens up exciting networking and collaboration opportunities that will drive our progress forward.
We thank UNIIQ for their trust and support, and we are eager to continue our journey to bring cutting-edge medical solutions to patients worldwide.
